Table 1 Clinical and Tumor Characteristics
Characteristic* | Normal/mildly Reduced RV Function† (n = 36) | Reduced RV Function (n = 33) | P-value | No/minimal TR/PR‡ (n = 29) | Mild to Severe TR/PR (n = 40) | P-value |
|---|---|---|---|---|---|---|
Gender | 0.06 | 0.22 | ||||
Men | 13 (36%) | 20 (61%) | 11 (38%) | 22 (55%) | ||
Women | 23 (64%) | 13 (39%) | 18 (62%) | 18 (45%) | ||
Age§ | 63 (36-81) | 65 (33-83) | 0.87 | 60 (36-75) | 68 (33-83) | <0.001 |
Smoking | 5 (15%) | 9 (28%) | 0.23 | 5 (17%) | 9 (24%) | 0.56 |
Illness duration (yrs) | 3.4 (0.8-7.5) | 5.1 (2.3-6.8) | 0.33 | 2.3 (0.7-5.2) | 5.3 (2.6-7.8) | 0.01 |
1° tumor size (mm) ∥ | 20 (15-27) | 20 (15-30) | 0.44 | 20 (16-30) | 19 (15-29) | 0.53 |
Carcinoid syndrome¶ | 30 (83%) | 29 (88%) | 0.74 | 21 (72%) | 38 (95%) | 0.01 |
Ki 67# | 2% (0-10) | 2.5% (1-25) | 0.16 | 2% (1-10) | 2% (0-25) | 0.20 |
U-5HIAA** | 6 (2-19) | 19 (4-29) | 0.08 | 7 (2-19) | 10 (3-30) | 0.21 |
CgA†† | 14 (6-24) | 26 (12-82) | 0.02 | 16 (6-37) | 19 (9-79) | 0.31 |
Liver metastases | 30 (83%) | 30 (91%) | 0.48 | 27 (93%) | 33 (83%) | 0.29 |
Size (mm) ‡‡ | 15 (7-19) | 15 (13-25) | 0.18 | 14 (9-19) | 17 (11-24) | 0.22 |
Number | 6 (1-12) | 11 (6-20) | 0.01 | 6 (1-10) | 11 (5-20) | 0.03 |